Document is current

Article History

Received: 5 August 2021

Accepted: 6 February 2022

First Online: 18 April 2022

Declarations

:

: Not applicable.

: Not applicable.

: RJP: Research investigator: Clementia/Ipsen, Regeneron; Advisory board: President of the International Clinical Council (ICC) on FOP; CBG: IFOPA Board Member, IFOPA Executive Committee Member, FOP Friends Chair and Trustee, International President’s Council Chair; AC: Trustee of the Radiant Hope Foundation, Trustee of the Ian Cali FOP Research Fund/Penn Medicine, Co-founder and Advisory Board member of the Tin Soldiers Patient Identification Program, Executive Producer of the Tin Soldiers documentary, Past IFOPA Chairman of the Board, Executive Associate of the International Clinical Council (ICC) on FOP; MD: Member of the Rare Bone Disease Alliance Steering Committee and the Global Genes RARE Global Advocacy Leadership Council; PLRD: Research investigator: Clementia/Ipsen; Member of the International Clinical Council on FOP; MR: Fundación FOP Board Member, IFOPA member; CS: Vice Chairman of the Board, Board member of Tin Soldiers Patient Identification Program, Member of the International Clinical Council (ICC) on FOP, Member of the IFOPA Medical Advisory Board, Tin Soldiers Board Member, Member of the International President’s Council; KG, CH, AK, HN: No competing interests to declare; FSK: Research investigator: Clementia/Ipsen, Regeneron; Advisory Board: IFOPA Medical Advisory Board; Founder and Past-President of the International Clinical Council (ICC) on FOP; Chair of the Publications Committee of the ICC. In April 2019, Ipsen acquired Clementia Pharmaceuticals.